scholarly journals Fenofibrate-Induced Lichenoid Drug Eruption: A Rare Culprit

2017 ◽  
Vol 9 (3) ◽  
pp. 236-242 ◽  
Author(s):  
Fayeza Mohammed ◽  
Laura L. Wally ◽  
Jeffrey E. Karaban ◽  
Vijaya B. Reddy ◽  
Yongsuk Lertratanakul

A lichenoid drug eruption is a rare side effect which can occur following the administration of several different medications. Here we describe a unique case of fenofibrate as the causative agent of a lichenoid drug eruption. This case highlights a rare and clinically significant dermatologic side effect of fenofibrate. In addition, we report a potential familial association which underscores the potential for underlying genetic mechanisms to be contributory to lichenoid drug eruptions. A reminder of the physical characteristics of lichen planus, knowledge of the temporal relation between administration of medications and a lichenoid drug eruption, recognition of the effect of UV exposure on lichenoid drug eruptions, and realization for the potential of symptoms to persist despite discontinuation of an offending agent can aid practitioners in promptly diagnosing lichenoid drug eruptions and initiating appropriate therapy.

2013 ◽  
Vol 52 (12) ◽  
pp. 1572-1574 ◽  
Author(s):  
Demet Cicek ◽  
Bengu Cobanoglu ◽  
Rahime İnci ◽  
Selma Bakar Dertlioglu ◽  
Ibrahim Kokcam ◽  
...  

2021 ◽  
pp. 878-883
Author(s):  
Neethi Dasu ◽  
Yaser Khalid ◽  
Kirti Dasu ◽  
Lucy Joo ◽  
Brian Blair

Kayexalate has been used in the USA since 1975 for the treatment of hyperkalemia. Prior case reports have shown that sorbitol added to kayexalate has been known to cause rare side effects of colonic necrosis. We present a unique case report of gastric pneumatosis as a complication of kayexalate.


2016 ◽  
Vol 2 (1) ◽  
pp. 41
Author(s):  
ManjeetNaresh Ramteke ◽  
AnuradhaAshok Bhide

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Florence Jaguga

Abstract Background Stuttering is a rare side effect of clozapine. It has been shown to occur in the presence of one or more factors such as abnormal electrophysiological findings and seizures, extrapyramidal symptoms, brain pathology, and a family history of stuttering. Few case reports have documented the occurrence of clozapine-induced stuttering in the absence of these risk factors. Case presentation A 29-year-old African male on clozapine for treatment-resistant schizophrenia presented with stuttering at a dosage of 400 mg/day that resolved with dose reduction. Electroencephalogram findings were normal, and there was no clinical evidence of seizures. The patient had no prior history or family history of stuttering, had a normal neurological examination, and showed no signs of extrapyramidal symptoms. Conclusion Clinicians ought to be aware of stuttering as a side effect of clozapine, even in the absence of known risk factors. Further research should investigate the pathophysiology of clozapine-induced stuttering.


Rheumatology ◽  
2021 ◽  
Author(s):  
G M Murray ◽  
S Kheng Ng ◽  
D Beasley ◽  
L Johansen ◽  
A V Ramanan

Author(s):  
Varitsara Mangkorntongsakul ◽  
Chinthuran Thilagarajan ◽  
Fatemeh Arianejad ◽  
Vicki Howard ◽  
Saxon D Smith ◽  
...  

2008 ◽  
Vol 27 (2) ◽  
pp. 229-232 ◽  
Author(s):  
V. Boussaud ◽  
N. Daudet ◽  
E.M. Billaud ◽  
A. Lillo-Le Louet ◽  
P. Chevalier ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document